Abstract:Background: Pathological cardiac fibrosis and hypertrophy, the common features of left ventricular remodeling, often progress to heart failure. Forkhead box transcription factor P1 (Foxp1) in endothelial cells (ECs) has been shown to play an important role in heart development. However, the effect of EC-Foxp1 on pathological cardiac remodeling has not been well clarified. This study aims to determine the role of EC-Foxp1 in pathological cardiac remodeling and the underlying mechanisms. Methods: Foxp1 EC-specific loss-of-function and gain-of-function mice were generated, and an angiotensin II infusion or a transverse aortic constriction operation mouse model was used to study the cardiac remodeling mechanisms. Foxp1 downstream target gene transforming growth factor-beta 1 (TGF-beta 1) was confirmed by chromatin immunoprecipitation and luciferase assays. Finally, the effects of TGF-beta 1 blockade on EC-Foxp1 deletion-mediated profibrotic and prohypertrophic phenotypic changes were further confirmed by pharmacological inhibition, more specifically by RGD-peptide magnetic nanoparticle target delivery of TGF-beta 1-siRNA to ECs. Results: Foxp1 expression is significantly downregulated in cardiac ECs during angiotensin II-induced cardiac remodeling. EC-Foxp1 deletion results in severe cardiac remodeling, including more cardiac fibrosis with myofibroblast formation and extracellular matrix protein production, as well as decompensated cardiac hypertrophy and further exacerbation of cardiac dysfunction on angiotensin II infusion or transverse aortic constriction operation. In contrast, EC-Foxp1 gain of function protects against pathological cardiac remodeling and improves cardiac dysfunction. TGF-beta 1 signals are identified as Foxp1 direct target genes, and EC-Foxp1 deletion upregulates TGF-beta 1 signals to promote myofibroblast formation through fibroblast proliferation and transformation, resulting in severe cardiac fibrosis. Moreover, EC-Foxp1 deletion enhances TGF-beta 1-promoted endothelin-1 expression, which significantly increases cardiomyocyte size and reactivates cardiac fetal genes, leading to pathological cardiac hypertrophy. Correspondingly, these EC-Foxp1 deletion-mediated profibrotic and prohypertrophic phenotypic changes and cardiac dysfunction are normalized by the blockade of TGF-beta 1 signals through pharmacological inhibition and RGD-peptide magnetic nanoparticle target delivery of TGF-beta 1-siRNA to ECs. Conclusions: EC-Foxp1 regulates the TGF-beta 1-endothelin-1 pathway to control pathological cardiac fibrosis and hypertrophy, resulting in cardiac dysfunction. Therefore, targeting the EC-Foxp1-TGF-beta 1-endothelin-1 pathway might provide a future novel therapy for heart failure.

Dickkopf-3 attenuates pressure overload-induced cardiac remodelling.

Dickkopf-3 protects against cardiac dysfunction and ventricular remodelling following myocardial infarction

DKK3 Overexpression Attenuates Cardiac Hypertrophy and Fibrosis in an Angiotensin-Perfused Animal Model by Regulating the ADAM17/ACE2 and GSK-3β/β-catenin Pathways

A Cytokine-Like Protein Dickkopf-Related Protein 3 is Atheroprotective.

Dickkopf-3 Ablation Attenuates the Development of Atherosclerosis in ApoE-Deficient Mice.

Smad3 Mediates Cardiac Inflammation and Fibrosis in Angiotensin II–Induced Hypertensive Cardiac Remodeling

Novel Role for Pleckstrin Homology-Like Domain Family A, Member 3 in the Regulation of Pathological Cardiac Hypertrophy.

Tumor Necrosis Factor Receptor-Associated Factor 3 is A Positive Regulator of Pathological Cardiac Hypertrophy

The Akt Pathway Mediates the Protective Effects of Myeloid Differentiation Protein 1 in Pathological Cardiac Remodelling

C1q-tumour Necrosis Factor-Related Protein-3 Exacerbates Cardiac Hypertrophy in Mice.

Dickkopf 3: a Novel Target Gene of Mir-25-3p in Promoting Fibrosis-Related Gene Expression in Myocardial Fibrosis.

Endothelial Forkhead Box Transcription Factor P1 Regulates Pathological Cardiac Remodeling Through Transforming Growth Factor-β1–Endothelin-1 Signal Pathway

Histone lysine dimethyl-demethylase KDM3A controls pathological cardiac hypertrophy and fibrosis

DGKζ Deficiency Promotes Maladaptive Cardiac Hypertrophy Through Modulating Autophagy Via Mtor/tfeb Signaling Pathway

Angiotensin-Converting Enzyme 3 (Ace3) Protects Against Pressure Overload-Induced Cardiac Hypertrophy

Tnni3k, A Cardiac-Specific Kinase, Promotes Physiological Cardiac Hypertrophy In Transgenic Mice

Dickkopf-1 Promotes Vascular Smooth Muscle Cell Proliferation and Migration Through Upregulating UHRF1 During Cyclic Stretch Application

Ca2+/Calmodulin-Dependent Protein Kinase II Regulation by Inhibitor of RIPK3 Protects Against Cardiac Hypertrophy

DKK3 (dickkopf 3) Alters Atherosclerotic Plaque Phenotype Involving Vascular Progenitor and Fibroblast Differentiation into Smooth Muscle Cells

Novel Protective Role of Myeloid Differentiation 1 in Pathological Cardiac Remodelling

Novel Role for Caspase-Activated DNase in the Regulation of Pathological Cardiac Hypertrophy.